2020 IPO
Annexon Biosciences Stock
Biotechnology company developing therapeutics for neurodegenerative and autoimmune disorders
Sign up today and learn more about Annexon Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Annexon Biosciences Stock
Annexon Biosciences is the development of therapeutic products that halt the progression of complement-mediated neurodegeneration (CMND).
Funding History
| August 2011 | $1000K |
|---|---|
| December 2014 | $34.0M |
| June 2016 | $44.0M |
| December 2018 | $75.0M |
Management
Chief Scientific Officer
Ted Yednock
Co-Founder
Arnon Rosenthal
President & Chief Executive Officer
Douglas Love
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
